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Abstract
Dialysis patients with chronic renal failure receiving deferoxamine for treating iron overload
are uniquely predisposed for mucormycosis, which is most often caused by Rhizopus ory-
zae. Although the deferoxamine siderophore is not secreted byMucorales, previous studies
established that Rhizopus species utilize iron from ferrioxamine (iron-rich form of deferoxa-
mine). Here we determined that the CBS domain proteins of Fob1 and Fob2 act as recep-
tors on the cell surface of R. oryzae during iron uptake from ferrioxamine. Fob1 and Fob2
cell surface expression was induced in the presence of ferrioxamine and bound radiola-
beled ferrioxamine. A R. oryzae strain with targeted reduced Fob1/Fob2 expression was im-
paired for iron uptake, germinating, and growing on medium with ferrioxamine as the sole
source of iron. This strain also exhibited reduced virulence in a deferoxamine-treated, but
not the diabetic ketoacidotic (DKA), mouse model of mucormycosis. The mechanism by
which R. oryzae obtains iron from ferrioxamine involves the reductase/permease uptake
system since the growth on ferrioxamine supplemented medium is associated with elevated
reductase activity and the use of the ferrous chelator bathophenanthroline disulfonate abro-
gates iron uptake and growth on medium supplemented with ferrioxamine as a sole source
of iron. Finally, R. oryzaemutants with reduced copies of the high affinity iron permease
(FTR1) or with decreased FTR1 expression had an impaired iron uptake from ferrioxamine
in vitro and reduced virulence in the deferoxamine-treated mouse model of mucormycosis.
These two receptors appear to be conserved inMucorales, and can be the subject of future
novel therapy to maintain the use of deferoxamine for treating iron-overload.
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Author Summary
Deferoxamine is an iron-chelating agent often used to treat patients with acute iron poi-
soning, such as seen in dialysis patients with chronic renal failure. These patients are
uniquely predisposed to a deadly fungal infection, called mucormycosis, because deferoxa-
mine supplies iron that supports growth of fungi causing this infection. Apart from the im-
portant basic knowledge in delineating iron uptake mechanisms in cells, understanding
how organisms causing mucormycosis obtain iron from ferrioxamine (deferoxamine
bound with iron) is likely to develop strategies to treat mucormycosis infections in patients
treated with deferoxamine. In this study we identified two cell surface receptors that bind
ferrioxamine and facilitate iron uptake in Rhizopus oryzae, the most causative fungus of
mucormycosis. These receptors are required for full virulence of R. oryzae in mice treated
with deferoxamine. From genetic and biochemical studies it appears that the fungus binds
ferrioxamine via these two receptors then liberates iron through a chemical modification
step prior to transporting into the fungal cell without the internalization of deferoxamine.
Introduction
Mucormycoses, caused by fungi in the orderMucorales, are life threatening infections that af-
flict immunosuppressed patients due to neutropenia, corticosteroids treatment, hyperglycemia,
and trauma [1,2]. These relatively uncommon infections, mainly caused by Rhizopus spp., have
been steadily increasing in numbers for the last three decades [3,4]. Despite the current aggres-
sive treatment options against mucormycosis which constitutes reversal of immunosuppressive
predisposing factors, surgical removal of infected foci (when possible) and antifungal therapy,
overall mortality remains at>50% and approaches 100% for patients with brain involvement,
prolonged neutropenia and hematogenously disseminated disease [5,6,7,8]. Clearly, novel
strategies to prevent and/or treat the disease are critically needed.
Clinical observations strongly link the ability of organisms to obtain iron from the host
as an essential virulence factor ofMucorales [9,10]. For example, hyperglycemia, diabetic
ketoacidosis and other forms of acidosis predispose the host to mucormycosis because of
compromised ability of transferrin to chelate iron, thereby making iron available to invading
organisms [9,11,12]. Similarly, dialysis patients with chronic renal failure who suffer from iron
overload due to blood transfusion were historically treated with the bacterial siderophore,
deferoxamine [13,14,15]. These patients were uniquely susceptible to lethal form of mucormy-
cosis [13,15,16]. Although deferoxamine is an iron-chelator from the perspective of the human
host, Rhizopus spp. utilize ferrioxamine (deferoxamine + Fe3+) as a xenosiderophore to obtain
previously unavailable iron [17,18]. It was also reported that Rhizopus obtains iron from
ferrioxamine by intracellular transport of the reduced iron without deferoxamine internaliza-
tion [18]. Recently, we found treatment of Rhizopus-infected mice with the iron chelators
deferiprone [19] or deferasirox [20] (which are not utilized as xenosiderophores by Rhizopus)
markedly improved survival. These results further confirm the unique importance of iron in
the pathogenesis of mucormycosis. In the current study, we sought to identify the fungal cell
surface protein that binds to ferrioxamine and its role in the pathogenesis of mucormycosis.
We provide evidence that the ferrioxamine binding (Fob) cell surface proteins (namely Fob1
and Fob2) are the fungal receptors that mediate attachment to ferrioxamine, thereby facilitat-
ing fungal iron uptake from this xenosiderophore via the reductase/high affinity iron permease
pathway. Importantly, Fob1 and Fob2 are inducible proteins that are required for full virulence
of R. oryzae only in the deferoxamine-treated mouse model of mucormycosis.
Ferrioxamine Receptors and Mucormycosis Pathogenesis
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Results
Identification of putative ferrioxamine receptors
To isolate putative ferrioxamine receptor(s), R.oryzae protoplasts were allowed to regenerate in
the presence or absence of ferrioxamine, which is the iron-rich form of the bacterial sidero-
phore, deferoxamine [21]. SDS-PAGE analysis of proteins demonstrated the presence of a
major band at ~ 70 kDa in cell-free supernatants concentrated from R. oryzae regenerating
protoplasts in the presence, but not in the absence, of ferrioxamine. Other minor bands were
also detected around 40kDa in supernatants from medium with or without ferrioxamine (Fig
1A). For a protein to act as a receptor it must bind to ferrioxamine. Therefore, we incubated
the protein preparations collected from these supernatants with radiolabeled ferrioxamine
(deferoxamine+55Fe) prior to running on a non-denaturing PAGE followed by autoradio-
graphy. A band from proteins concentrated in the supernatant collected from protoplasts re-
generated in the presence of ferrioxamine, but not in the absence of ferrioxamine, bound to
radiolabeled ferrioxamine (Fig 1B). Because the 70 kDa band was abundant in the ferrioxa-
mine-containing supernatant and absent in the supernatant concentrated from media lacking
ferrioxamine, we sequenced this band by MALDITOF MS/MS. The overwhelming indentified
protein was predicted to be encoded by RO3G_11000 (352 amino acid), which is annotated as
a CBS-domain-containing protein (http://www.broadinstitute.org/, see Discussion for CBS-do-
main protein definition) in the R. oryzae 99-880 database (also known as R. delemar) (Table 1).
We also found that the ORF RO3G_11000 shares ~80% identity with ORF RO3G_05087 (350
amino acid) at the DNA or protein levels. The RO3G_05087 and RO3G_11000 ORFs are pre-
dicted to encode proteins with ~ 39 kDa in size and were named FOB1, and FOB2, respectively.
These predicted proteins have 4 putative CBS domains and multiple possible N- and O-glyco-
sylation sites (Fig 1C). Interestingly and despite the presence of Fob2 protein in the supernatant
of regenerated protoplasts, we did not observe classic features of secreted proteins such as N-
terminal signal peptide or C-terminus GPI-anchor sequence. However, using the MEMSAT
program it was predicted that Fob1 and Fob2 proteins have one to two transmembrane do-
mains with an extracellular fragment and a cytoplasmic tail (S1 Fig). Further localization analy-
sis using antibody staining confirmed the surface localization of Fob proteins (see below).
We also examined whether this family of genes was present in otherMucorales known to
cause mucormycosis. Blast search of FOB1 and FOB2 confirmed the presence of orthologs of
FOB1/2 in everyMucorales genome published thus far with percent identity at the amino acid
levels ranging from 42% forMortierella verticillata FOB1 ortholog to 78% forMucor circinel-
loides f. circinelloides FOB2 (Table 2). Orthologs from other fungi were also found with lesser
degree of identity (e.g. ~ 20% for Aspergillus, Saccharomyces cerevisiae, and Candida).
Putative ferrioxamine receptors are inducible by ferrioxamine, likely to
oligomerize, and expressed on the cell surface
Because radiolabeled ferrioxamine bound to a band in protein preparations from supernatants
collected from regenerated protoplasts in the presence of ferrioxamine and not in the sidero-
phore’s absence (Fig 1B), we reasoned that the ferrioxamine receptor is likely induced by fer-
rioxamine. To test if FOB2 and its FOB1 homologue fulfill this criterion, we cultured R. oryzae
99-880 in medium containing ferrioxamine, FeCl3, deferoxamine, rhizoferrin (a siderophore
produced by Rhizopus [18,22]), or Fe3+ containing rhizoferrin as the sole source of iron prior
to analyzing the expression of FOB1 and FOB2 by qRT-PCR. As can be seen in Fig 2A, only the
iron-rich ferrioxamine consistently enhanced the expression of FOB1 and FOB2 by ~ 9 fold vs.
any other condition. Neither the iron depleted ferrioxamine (i.e. deferoxamine), nor rhizoferrin
Ferrioxamine Receptors and Mucormycosis Pathogenesis
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with or without iron induced the expression of either FOB1 or FOB2. However, the presence of
FeCl3 as a source of iron instead of ferrioxamine resulted in a modest increase in the expression
of FOB2.
If FOB2 and/or FOB1 indeed encode a ferrioxamine receptor, the lack of their expression by
deferoxamine indicated that iron uptake from radiolabeled ferrioxamine should not be inhib-
ited by deferoxamine but rather by cold ferrioxamine. To test this possibility, iron uptake of
55Fe3+ from ferrioxamine by R. oryzae was carried out at increased concentrations of cold fer-
rioxamine or deferoxamine. Cold ferrioxamine, but not deferoxamine, inhibited 55Fe3+ uptake
Fig 1. Detection of the ferrioxamine putative receptor in the cell surfacematerial ofR. oryzae. Cell
surface material was collected from regenerating R. oryzae protoplasts grown in iron-limited medium
with (+Ferri) or without (-Ferri) deferoxamine. Samples were separated on SDS-PAGE and visualized by
Coomassie blue (A). Additionally, samples were mixed with [55Fe]ferrioxamine[69] then analyzed by non-
denaturing PAGE followed by autoradiography (B). Two putative and closely related ORFs were identified
and named FOB1 and FOB2. Highlighted area denotes the four CBS domains while underlined amino acids
indicate potential N- andO-glycosylation sites (C).
doi:10.1371/journal.ppat.1004842.g001
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by>70% when introduced at 3–10 fold higher concentrations than the radiolabeled ferrioxa-
mine (Fig 2B).
Because FeCl3 had a modest effect on the expression of FOB1 and FOB2 when compared to
ferrioxamine, while deferoxamine had no effect on their expression, this implicated ferric iron
as a critical signal for triggering the expression of these two genes. We studied the expression of
FOB1 and FOB2 in response to varying concentrations of FeCl3. As can be seen in Fig 2C,
FeCl3, modestly enhanced the expression of both genes in a non-linear manner. Collectively,
these results show that the expression of FOB1 and FOB2 is maximal only when the sidero-
phore is iron–rich (i.e. ferrioxamine), the iron-depleted form (i.e. deferoxamine) does not in-
duce nor it inhibits iron uptake from ferrioxamine, and the native siderophore of rhizoferrin
does not induce the expression of these two genes.
To study if enhancement in FOB1 and FOB2 gene expression resulted in enhanced protein
expression on R. oryzae cell surface, we raised antibodies against an E. coli-produced Fob2 pro-
tein (rFob2p) by vaccinating mice and used these polyclonal antibodies to detect the expression
of Fob proteins on R. oryzae cell surface by FACS analysis. Sera collected from mice vaccinated
with rFob2p + adjuvant had an antibody titer of 1:32,000 vs. a titer of 1:1600 of sera collected
from mice vaccinated with the adjuvant alone. Additionally, sera collected from rFob2p vacci-
nated mice reacted to the E. coli produced Fob2 protein as well as a protein band isolated from
whole cell protein extract of R. oryzae wild-type hyphae only when grown in the presence of
ferrioxamine. These two bands were detected at ~40 kDa with slight difference in size which is
likely attributed to the presence of His-tag on the rFob2p. Also the antibodies did not detect
any bands from whole cell extracts of R. oryzae strain in which both FOB1 and FOB2 were
down regulated regardless of the presence or absence of ferrioxamine in the growth medium
(see below for FOB1/FOB2 inhibition by RNA-i) (Fig 3A for Western blot and S2A Fig for
Table 1. MALDITOFMS/MS sequence results of the 70 kDa band detected in the supernatant of regenerated protoplasts of R. oryzae grown in the
presence of ferrioxamine.
Rank order Protein Protein mass (kDa) Protein score Queries matched
1 RO3G_11000 (Fob2 protein) 38.9 55 15
2 RO3G_00635 (Hypothetical protein) 94 33 13
3 RO3G_04771 (Hypothetical protein) 78 30 6
4 RO3G_03963 (Hypothetical protein) 98.8 30 5
5 RO3G_01777 (phosphoribosyl-glycinamide formyltransferase) 22.7 30 4
6 RO3G_01375 (Hypothetical protein) 40.9 30 4
Protein scores of >29 was calculated for the 5% confidence threshold.
doi:10.1371/journal.ppat.1004842.t001
Table 2. Sequence homology of FOB1/2 genes fromR. oryzae 99-880 to possibleMucorales orthologs.
Strain ID Mucorales Source % ID FOB1 % ID FOB2
JMRC:FSU:96821 Lichtheimia corymbifera Jena Uni ND 59 (355)
JMRC FSU:6197 Lichtheimia ramosa Jena Uni ND 58 (355)
NRRL 6337 Mortierella verticillata Broad Inst. 42 (327) 45 (327)
1006 PhL Mucor circinelloides f. circinelloides Broad Inst. 57 (330) 78 (356)
CBS 183.67 Rhizomucor pusillus Genozymes ND 59 (346)
Numbers in brackets represent the orthologs length in amino acids.
% ID denotes % identity.
ND indicate not detected.
doi:10.1371/journal.ppat.1004842.t002
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SDS-PAGE gel picture). Analysis of the recognized bands by nano-LC ESI MS/MS confirmed
the identity of the proteins to Fob2p (Table 3). Interestingly, we could not detect the protein in
cell-free supernatants collected from media containing R. oryzae wild-type or FOB1/FOB2 inhi-
bition mutant grown in the presence or absence of ferrioxamine (Fig 3B for Western blot, and
S2B Fig for SDS-PAGE gel picture). Furthermore, radiolabeled ferrioxamine reacted to crude
cell protein extracts or proteins immunoprecipitated by anti-Fob2 antibodies from R. oryzae
wild-type whole cell extracts only when grown in a medium containing ferrioxamine (Fig 3C).
Finally, the immunoprecipitated band from the whole cell extract of R. oryzae wild-type cells as
well as the immunoprecipitated band from rFob2p had sizes of around 40 kDa (Fig 3D for
Western blot and S2C Fig for SDS-PAGE gel picture) similar to what noticed in Fig 3A. These
two immunoprecipitated bands were confirmed to be Fob2 protein by nano-LC ESI MS/MS
Fig 2. FOB1 and FOB2 expression is induced by ferrioxamine and to a lesser extent by ferric iron but not by deferoxamine. The expression of FOB1
and FOB2was studied in response to iron sources in vitro. (A) qRT-PCRwas used to study the expression of FOB1 and FOB2 in media without added iron,
10 μM of ferrioxamine, deferoxamine, rhizoferrin without Fe3+, rhizoferrin with Fe3+ or 100 μMFeCl3. (B) Cold ferrioxamine but not deferoxamine inhibits
55Fe3+ uptake from ferrioxamine (introduced at a concentration of 10 μM). (C) Compared to ferrioxamine, FeCl3 demonstrated modest and non-linear
increase in FOB1 and FOB2 expression as determined by qRT-PCR. (D) Flow cytometry using antiFob2p polyclonal antibodies demonstrated the cell
surface expression of Fob1 and Fob2 proteins in medium containing ferrioxamine but not in medium without iron supplement. Error bars represent the
standard deviation of the mean from at least two independent assays (n> 6 per group). *P<0.05 vs. no iron, while **P<0.001 vs. no iron or FeCl3.
doi:10.1371/journal.ppat.1004842.g002
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(Table 3). Because immunoprecipitation of whole cell extracts of R. oryzae wild-type cells re-
sulted in almost no apparent band on SDS-PAGE gel, we reasoned that the majority of the pro-
tein was retained bound to the antibody coated beads. Therefore, we ran the beads on a
SDS-PAGE gel after boiling them. Coomassie Brilliant Blue stain showed two major bands at
~40 kDa as well as ~70 kDa (S2D Fig). Because the 70 kDa band corresponded to the size of
the identified Fob2 protein from concentrated supernatant of regenerated protoplasts grown in
ferrioxamine-containing medium (Fig 1A), we sequenced this band as well as the 40 kDa band
by nano-LC ESI MS/MS. The major protein present in these two bands was identified as Fob2p
Fig 3. Western blot analysis demonstrating that Fob proteins are cell-associated, not secreted, and bind to radiolabeled ferrioxamine. Antibodies
were raised against E. coli-produced Fob2 protein and used to study the expression pattern of Fob proteins. (A) Western blot analysis of whole cell proteins
extracted from R. oryzae wild-type or R. oryzaemutant with dual inhibition of FOB1/ FOB2 by RNA-i (see Fig 6 for generation of this mutant). (B) Western blot
analysis of supernatant (cell-free) collected from R. oryzae wild-type hyphae or R. oryzaemutant with dual inhibition of FOB1/ FOB2 growing for overnight in
media with or without ferrioxamine. (C) Whole cell proteins from R. oryzae wild-type grown in medium with or without ferrioxamine were loaded on membrane
under non-denaturing conditions prior to mixing with [55Fe]ferrioxamine[69] then analyzed with autoradiography. Also, Fob proteins from the same crude cell
wall extracts were separated by immunoprecipitation using anti-IgG Fob2 antibodies coupled to protein G beads column prior to incubating with [55Fe]
ferrioxamine under non-denaturing conditions. The beads were washed extensively with washing buffer prior to spotting them on membrane followed by
autoradiography. (D) Western blot analysis of whole cell proteins extracted from R. oryzae wild-type or R. oryzaemutant with dual inhibition of FOB1/ FOB2
following immunoprecipitation using anti-IgG Fob2 antibodies as in C. rFob2p was included in A, B, and D as a control showing the expected band size of ~40
kDa (bands in A, B and D below 35 kDa from rFob2p lane represent degradation of rFob2p. Note, that the marker is overlaid on each of the western blots to
determine band sizes.
doi:10.1371/journal.ppat.1004842.g003
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Table 3. nano-LC ESI MS/MS sequence data of 40 or 70 kDa bands fromwhole cell extracts ofR. oryzaewild-type before and after
immunoprecipitation.
Accession Description Σ# Unique
Peptides
Band
1
Band 2 Band 3 Band 4 Band
5
Amino
acid #
MW
[kDa]
Calc.
pI
I1CCV9 Uncharacterized protein R. oryzae
RO3G_11000 (Fob2p)
22 3.6E9 2.5E9 4.2E9 5.1E8 1.4E9 351 38.7 6.37
I1BY51 Glyceraldehyde-3-phosphate
dehydrogenase 3 R. oryzae
RO3G_05836
9 0 6.7E6 0 0 1.3E9 338 36.1 6.16
I1CEK5 Transaldolase R. oryzae RO3G_11596 14 0 2.4E7 0 0 3.8E9 322 35.7 5.40
I1BPM3 Uncharacterized protein R. oryzae
RO3G_02857
7 0 0 0 0 1.2E8 286 30.9 6.07
I1CJ47 Glyceraldehyde-3-phosphate
dehydrogenase 1 R. oryzae
RO3G_13188
7 0 0 0 0 5.4E8 333 35.6 7.84
I1C0C1 Uncharacterized protein R. oryzae
RO3G_06606
6 0 0 0 0 1.9E7 259 28.0 5.54
I1C4E8 Glyceraldehyde-3-phosphate
dehydrogenase 2 R. oryzae
RO3G_08033
5 0 8.6E6 0 0 8.5E8 338 35.9 6.57
I1BW63 UDP-glucose 4-epimerase R. oryzae
RO3G_05148
7 0 0 0 0 4.0E7 354 38.6 6.55
I1CCY5 Saccharopine dehydrogenase R.
oryzae RO3G_11026
9 0 0 0 0 1.7E8 451 49.3 5.66
I1C642 Uncharacterized protein R. oryzae
RO3G_08627
6 0 0 0 0 1.9E7 364 40.3 5.69
I1CLC6 Endopeptidase R. oryzae
RO3G_13967
9 1.9E6 1.7E7 1.3E8 0 1.5E9 401 44.4 4.87
I1BQ83 3-isopropylmalate dehydrogenase R.
oryzae RO3G_03067
7 0 0 0 0 2.1E7 374 39.8 5.41
I1CD60 Uncharacterized protein R. oryzae
RO3G_11101
5 0 0 0 0 3.3E7 312 34.9 6.64
I1C3R1 Uncharacterized protein R. oryzae
RO3G_07796
8 0 0 2.1E7 0 2.2E7 579 63.6 6.24
I1BYI4 Uncharacterized protein R. oryzae
RO3G_05969
3 0 0 1.3E7 0 6.7E6 238 26.9 6.52
I1CLG1 Actin-2 R. oryzae RO3G_12558 3 9.3E7 1.3E8 7.6E7 4.630E7 3.6E7 375 41.7 5.58
I1BPT0 Transaldolase R. oryzae RO3G_02914 1 0 2.2E7 0 0 1.4E9 322 35.9 7.11
I1CKV3 ADP-ribosylation factor 1 R. oryzae
RO3G_13794
1 4.4E7 0 0 0 0 163 18.7 6.02
I1C2J3 Glucosamine-6-phosphate isomerase
1 R. oryzae RO3G_07378
1 0 0 0 0 0 298 33.4 6.48
I1C4Y4 Histone H4 R. oryzae RO3G_08122 1 1.8E7 1.3E7 0 0 0 103 11.4 11.36
I1BZG8 Uncharacterized protein R. oryzae
RO3G_06303
1 0 0 0 0 0 304 34.0 6.19
I1BVE5 Acetyl-CoA hydrolase R. oryzae
RO3G_04880
1 0 0 0 0 0 524 58.3 6.49
I1BTR0 Uncharacterized protein R. oryzae
RO3G_04295
2 0 0 0 0 1.3E7 421 45.8 4.15
I1CE02 Cyclin domain-containing protein R.
oryzae RO3G_11393
1 0 0 0 2.889E10 0 101 11.7 5.91
I1CEM3 Uncharacterized protein R. oryzae
RO3G_11614
1 0 0 0 0 9.4E6 162 18.4 6.18
I1BU17 Uncharacterized protein R. oryzae
RO3G_04402
2 0 0 0 5.672E6 7.4E6 510 57.7 5.17
(Continued)
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(Table 3). Collectively, these results demonstrated the specificity of the antibodies to Fob pro-
teins (the antibodies are likely to recognize Fob1 and Fob2 proteins due to the predicted similar
size and the 80% identity), strongly indicate that Fob proteins are cell-associated rather than se-
creted, and likely Fob2 proteins oligomerize under certain conditions to form larger
protein size.
To discern if the proteins are expressed on the cell surface or intracellularly, we used the
anti-Fob2p antibodies to stain R. oryzae germlings without permeabilization and studied the
Table 3. (Continued)
Accession Description Σ# Unique
Peptides
Band
1
Band 2 Band 3 Band 4 Band
5
Amino
acid #
MW
[kDa]
Calc.
pI
I1BPG1 Uncharacterized protein R. oryzae
RO3G_02795
2 0 0 0 0 4.2E6 543 58.8 5.73
I1BUG8 Uncharacterized protein R. oryzae
RO3G_04553
1 0 0 0 0 6.4E6 460 40.8 3.81
I1BKQ1 Chitin deacetylase R. oryzae
RO3G_01485
2 0 0 1.917E6 2.090E6 5.4E6 416 45.8 4.70
I1BLY8 Uncharacterized protein R. oryzae
RO3G_01922
1 0 0 0 0 4.4E6 485 45.6 3.65
I1BN63 Uncharacterized protein R. oryzae
RO3G_02347
1 0 0 0 0 1.3E7 386 42.3 9.19
I1BQ37 Uncharacterized protein R. oryzae
RO3G_03021
1 0 0 0 0 2.2E7 720 83.0 5.20
I1C8H3 Elongation factor Ts, mitochondrial R.
oryzae TSF1
1 0 0 0 0 7.1E6 331 35.9 6.02
I1BRN0 Uncharacterized protein R. oryzae
RO3G_03565
1 0 2.150E6 0 0 0 333 34.2 11.87
I1CDZ8 Uncharacterized protein R. oryzae
RO3G_11389
1 0 0 0 0 6.7E6 423 46.7 4.54
I1C1Z0 Uncharacterized protein R. oryzae
RO3G_07175
1 0 0 1.950E6 8.944E5 0 414 47.8 6.90
I1CDD0 Uncharacterized protein R. oryzae
RO3G_11171
1 0 0 7.562E6 0 0 438 49.8 5.45
I1C5V4 Uncharacterized protein R. oryzae
RO3G_08539
1 0 0 0 0 1.0E6 608 67.7 5.59
I1CM95 Uncharacterized protein R. oryzae
RO3G_14286
1 0 0 0 0 1.0E8 773 87.1 6.25
I1BP17 Uncharacterized protein R. oryzae
RO3G_02651
1 0 0 0 2.295E6 0 615 69.3 5.25
I1BLJ2 Pyruvate decarboxylase isozyme R.
oryzae RO3G_01776
1 0 0 0 0 3.2E6 560 61.3 5.45
I1BU19 Uncharacterized protein R. oryzae
RO3G_04404
1 0 0 0 0 1.5E6 614 67.9 6.27
I1CNE5 Uncharacterized protein R. oryzae
RO3G_14686
1 0 0 2.832E6 0 0 877 100.3 6.83
I1BKY8 Uncharacterized protein R. oryzae
RO3G_01572
1 0 0 0 0 0 700 77.5 7.30
I1BNP9 Uncharacterized protein R. oryzae
RO3G_02533
1 0 0 0 0 2.0E6 680 75.0 5.85
Band 1, rFob2p; Band 2, 40 kDa band of wild-type whole cell extract after immunoprecipitation; Band 3, 40 kDa band from beads coated with antiFob2
antibodies and used for immunoprecipitation of wild-type whole cell extract; Band 4, 70 kDa band from beads coated with antiFob2 antibodies and used
for immunoprecipitation of wild-type whole cell extract; Band 5, 40 kDa band of wild-type whole cell extract without immunoprecipitation; Calc. pI,
calculated isoelectric point.
doi:10.1371/journal.ppat.1004842.t003
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staining patterns by flow cytometry and confocal imaging. We noticed enhanced fluorescence
when R. oryzae wild-type cells were incubated with ferrioxamine and to a lesser extent when
FeCl3 was used as the sole source of iron compared to fungal cells grown in the absence of iron
source (Fig 2D). Confocal images using these antibodies also confirmed the cell surface locali-
zation of Fob proteins when the fungal germlings were incubated with ferrioxamine (S3 Fig).
Collectively, these results show that Fob proteins are expressed on the cell surface of germinat-
ed R. oryzae when ferrioxamine is present.
FOB1 or FOB2 gene silencing by RNA-i modestly reduces iron uptake and
slows growth ofR. oryzae on medium supplemented with ferrioxamine
To determine the role of these putative receptors in the uptake of iron from ferrioxamine, we
down regulated the expression of either of FOB1 or FOB2 (Fig 4A). As expected RNA-i con-
structs targeting either of the 2 ORFs resulted in ~90% inhibition of the expression of the
Fig 4. RNA-i targeting a single putative ferrioxamine receptor leads to compensatory effect with the other receptor. Plasmid pFOB1 (or pFOB2)
targeting inhibition of a single putative ferrioxamine receptor (A). Plasmid pFOB1 (B) or pFOB2 (C) successfully inhibited the expression of FOB1 and FOB2,
respectively as determined by qRT-PCR. However, a compensatory gene expression was observed in these transformants from the untargeted gene.
Results (n = 6 per group) were expressed as fold change in gene expression relative to gene expression in empty plasmid transformant. Error bars represent
the standard deviation of the mean from two independent assays. * and **P<0.05 compared to FOB1 and FOB2 expression in empty plasmid transformant,
respectively. Flow cytometry using antiFob2 polyclonal antibodies confirmed cell surface expression and the compensatory effect of the untargeted gene.
Induction and un-induction conditions were carried out using YNB with or without 10 μM ferrioxamine (D).
doi:10.1371/journal.ppat.1004842.g004
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intended target (i.e., FOB1 or FOB2). However, there was no inhibition in the expression of the
other gene (Fig 4B and 4C). In contrast, gene silencing of one FOB appeared to induce the ex-
pression of the other gene (e.g., a plasmid targeting FOB1 blocked expression of FOB1 expres-
sion, while FOB2 expression increased compared to cells transformed with empty plasmid and
grown in the presence of ferrioxamine) (Fig 4B and 4C). These findings were further confirmed
by immunostaining and FACS analysis. Cell surface expression of R. oryzae transformed with
RNA-i constructs targeting either FOB1 or FOB2 had reduced levels compared to R. oryzae
cells transformed with empty plasmid and grown in the presence of ferrioxamine. However,
this reduction in Fob protein expression did not reach the low levels of R. oryzae transformed
with the empty plasmid and grown in the absence of ferrioxamine (Fig 4D). These results indi-
cate that targeting one FOB gene results in a gene expression compensatory effect of the other.
Having generated the two R. oryzae strains with reduced expression in FOB1 or FOB2, we
compared the FOB1 or FOB2 silencing effect on the germination and growth of R. oryzae in a
medium supplemented with ferrioxamine. Silencing FOB1 or FOB2 did not have an effect on
the ability of R. oryzae to germinate in a medium supplemented with ferrioxamine (Fig 5A). In
contrast, R. oryzae transformed with RNA-i constructs targeting FOB1 or FOB2 gene expres-
sion resulted in 20–25% inhibition in growth on medium supplemented with ferrioxamine as a
sole source of iron when compared to R. oryzae wild-type or R. oryzae strain transformed with
the empty plasmid (Fig 5B). This reduction in growth is likely due to the compromised ability
of R. oryzae transformed with RNA-i constructs, targeting FOB1 or FOB2, to take up iron from
ferrioxamine since attenuation of either FOB1 or FOB2 reduced the ability of R. oryzae to take
up iron from radiolabeled ferrioxamine (Fig 5C). Although initial incubation periods of 1–2
hrs showed 60–80% reduction in 55Fe3+ uptake from ferrioxamine among R. oryzae trans-
formed with either RNA-i constructs targeting FOB1 or FOB2 compared to wild-type or R. ory-
zae transformed with empty plasmid, only 45% inhibition was detected after 4 hrs. This
modest reduction in iron uptake is likely due to the compensatory expression of the other
FOB gene.
Gene silencing of both FOB1 and FOB2 affects germination and
drastically reduces growth and iron uptake from ferrioxamine
Because gene silencing of one of the two FOB genes resulted in a modest effect on growth
and iron uptake from ferrioxamine, we employed a strategy of silencing both genes in a single
construct driven by a single pdc promoter (i.e., pFOB1/2) (Fig 6A). Upon transforming R. ory-
zae with this construct we were able to reduce the expression of FOB1 and FOB2 by>90%
(Fig 6B). Additionally, anti-Fob2p antibodies could not detect any bands from whole cell
protein extract of R. oryzae transformed with dual inhibition construct and grown in the pres-
ence or absence of ferrioxamine (Fig 3A). Moreover, the inhibition of FOB1/FOB2 translated to
near complete blocking of cell surface expression to the level of R. oryzae transformed with
the empty plasmid and grown in the absence of ferrioxamine (Figs 6C and S3). Furthermore,
the dual inhibition of FOB1 and FOB2 resulted in severe retardation of R. oryzae germination
(Fig 7A) and more than 40–50% inhibition in growth on medium supplemented with ferrioxa-
mine (Fig 7B) when compared to wild-type strain or R. oryzae transformed with empty plas-
mid. Finally, this retardation in germination and growth on ferrioxamine supplemented
medium was accompanied by up to 85% inhibition of iron uptake from ferrioxamine (Fig 7C).
Notably, there was no difference in growth of any of the three strains on FeCl3 supplemented
YNB medium (S4 Fig). Collectively, these results clearly implicate Fob1 and Fob2 proteins in
the uptake of iron from ferrioxamine.
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FOB1 and FOB2 are required for full virulence of R. oryzae in the
deferoxamine-treated but not the diabetic ketoacidotic mouse models
Because FOB1 and FOB2 are involved in iron uptake from ferrioxamine and since iron acquisi-
tion from the host is a critical virulence factor for mucormycosis [9,10,23], we hypothesized
that these two genes are critical determinants of virulence especially in a mouse model of defer-
oxamine treatment. To test this hypothesis, we compared the virulence of R. oryzae with
Fig 5. Single gene inhibition of FOB1 or FOB2 slightly reduced germination, growth and iron uptake of R. oryzaewhen ferrioxamine is used as a
sole source of iron. (A) To determine effect of gene inhibition on R. oryzae germination, cells were pregerminated in YNB+CSM-URAmedium supple-
mented with 10 μM ferrioxamine as a sole source of iron. At selected time intervals samples were taken from the medium and examined by light microscopy.
(B) To determine effect of gene inhibition on growth of R. oryzae, 105 spores of each strain were plated in the middle of the YNB+CSM-URA agar plates
supplemented with 10 μM ferrioxamine as a sole source of iron and the colony diameter (mm) was measured. Two independent transformants from each
construct were tested in triplicate (n = 9). *P <0.05 vs. wild-type and empty plasmid strains. (C) Single gene inhibition attenuated 55Fe3+ from ferrioxamine.
Two independent transformants from each construct were tested in triplicate (n = 9). *P <0.05 vs. Wild-type and empty plasmid strains. In B and C, error bars
represent the standard deviation of the mean from three independent assays.
doi:10.1371/journal.ppat.1004842.g005
Ferrioxamine Receptors and Mucormycosis Pathogenesis
PLOS Pathogens | DOI:10.1371/journal.ppat.1004842 May 14, 2015 12 / 33
reduced cell surface expression of Fob1 and Fob2 proteins to wild-type or to R. oryzae trans-
formed with empty plasmid using a deferoxamine-treated mouse model infected with a high
inocula of 105 spores or a lower dose of 103 spores. At the higher inoculum, R. oryzae cells har-
boring the empty plasmid was as virulent as wild-type R. oryzae (median survival time of 3
days of the wild-type and the empty plasmid strains infected mice P = 0.33). In contrast, mice
infected with one of two independently generated dual RNA-i transformants had attenuated
virulence with> 21 day median survival time and 1/2 of the mice surviving the lethal infection
(P<0.001). Further, at the lower inoculum of 103 spores, the two RNA-i transformants were
avirulent with 100% of the mice surviving the infection and appeared healthy at the termina-
tion of the experiment, while mice infected with R. oryzae transformed with the empty plasmid
had 80% mortality as early as 5 days post infection (P<0.001) (Fig 8A). In support of these
data, mice infected with the RNA-i transformant had ~ 2 log reduction in fungal burden in the
brains and kidneys (primary and secondary target organs) when compared to same organs
recovered from mice infected with wild-type cells or those infected with the empty plasmid
transformant (P<0.0001) (Fig 8B). To compare the severity of infection, we conducted histo-
pathological examination on mice organs infected with R. oryzae transformed with the empty
plasmid vs. those infected with R. oryzae transformed with RNA-i plasmid targeting both
Fig 6. Dual gene inhibition strategy completely abrogates FOB1 and FOB2 expression. Plasmid pFOB1/FOB2 targeting inhibition of the dual putative
ferrioxamine receptors (A). Plasmid pFOB1/FOB2 almost completely blocked FOB1 and FOB2, respectively as determined by qRT-PCR (B). Results were
expressed as fold change in gene expression relative to empty plasmid transformant. Error bars represent the standard deviation of the mean from two
independent assays. *P<0.005 compared to empty plasmid transformant. Flow cytometry using antiFob2 polyclonal antibodies confirmed the lack of
expression of either Fob1 or Fob2 proteins on the cell surface of R. oryzae transformed with pFOB1/FOB2 relative to cells transformed with empty plasmid
(C). Induction and un-induction conditions were carried out using YNB with or without 10 μM ferrioxamine.
doi:10.1371/journal.ppat.1004842.g006
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FOB1 and FOB2. Brains and kidneys harvested from mice infected with R. oryzae transformed
with RNA-i construct had minimal inflammation, edema and minimal to no presence of fungal
elements. In contrast, organs taken from mice infected with R. oryzae transformed with the
empty plasmid had abundance of fungal abscesses characterized by phagocyte infiltration and
substantial edema (Fig 8C).
To confirm that the RNA-i construct inhibited FOB1 and FOB2, we assessed the pattern of
in vivo expression of these genes in fungi recovered from the same mouse organs that were
Fig 7. Dual gene inhibition significantly attenuated the ability ofR. oryzae to germinate, grow and take up iron from ferrioxamine. (A) To determine
effect of dual gene inhibition on R. oryzae germination, cells were pregerminated in YNB+CSM-URAmedium supplemented with 10 μM ferrioxamine as a
sole source of iron. At selected time intervals samples were taken from the medium and examined by light microscopy. (B) To determine effect of dual
gene inhibition on growth of R. oryzae, 105 spores of each strain were plated in the middle of the YNB+CSM-URA agar plates supplemented with 10 μM
ferrioxamine as a sole source of iron and the colony diameter (mm) was measured. Four independent transformants were tested in triplicate (n = 9). *P <0.01
vs. wild-type and empty plasmid strains. (C) Dual gene inhibition attenuated 55Fe3+ from ferrioxamine. Four independent transformants were tested in
triplicate (n = 9). *P <0.05 vs. wild-type or empty plasmid strains. In B and C, error bars represent the standard deviation of the mean from three
independent assays.
doi:10.1371/journal.ppat.1004842.g007
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processed for tissue fungal burden. Relative to the fungal actin house keeping gene (ACT1),
FOB1 and FOB2 were expressed in organs collected from mice infected with the wild-type, or
the empty plasmid transformant. Importantly, fungal cells recovered from brain and kidneys
of mice infected with R. oryzae transformed with the RNA-i construct had ~80% reduction in
FOB1 or FOB2 gene expression (Fig 8D). These results indicate that FOB1 and FOB2 are
Fig 8. FOB1 and FOB2 are required for the full virulence ofR. oryzae in the deferoxamine-treated and not the DKAmousemodels. (A) Survival of
mice (n = 10 per arm) treated with three doses of deferoxamine (100 mg/kg/dose) via i.p. injection on day -1, 0, and +1 relative to intravenous infection with R.
oryzae strains. For the targeted inoculum of 1 x 105, mice were infected with wild-type (6.5 x 104 spores), R. oryzae transformed with empty plasmid (8.6 x 104
spores) or R. oryzae with dual attenuated expression of FOB1 and FOB2 (Dual 1 at 4.6 x 104 spores or Dual 2 at 3.6 x 104 spores). For the targeted inoculum
of 1 x 103, mice were infected with R. oryzae transformed with the empty plasmid (9.5 x 102 spores) or R. oryzaewith dual attenuated expression of FOB1 and
FOB2 (Dual 1 at 7.9 x 102 spores or Dual 2 at 4.9 x 102 spores). *P<0.001 compared to mice infected with wild-type or R. oryzae transformed with empty
plasmid. (B) Tissue fungal burden (determined by qPCR) of target organs (brains and kidneys) harvested frommice (n = 10 per arm) infected with wild-type
(7 x 104 spores), R. oryzae transformed with empty plasmid (5.7 x 104 spores) or R. oryzae with dual attenuated expression of FOB1 and FOB2 (4.8 x 104
spores). Data are expressed as median ± interquartile range. y axis value represents the lower limit of detection in the assay. *P<0.05 compared to tissues
harvested frommice infected with wild-type or empty plasmid transformant. (C) Histopathological examination (H&E stain) of target organs revealed
minimal inflammation and fungal elements in brains and kidneys of mice infected with RNA-i transformant, while organs collected from the empty plasmid
transformant infected mice had abscesses with abundant hyphae (arrows) and neutrophil infiltration. Magnification of 400 x. (D) In vivo expression of FOB1
and FOB2 genes in brain and kidneys harvested frommice infected with wild-type, empty plasmid or RNA-i dual transformant as determined by qRT-PCR
using specific primers to each of the FOB genes. Data are expressed as mean ± SD. * P<0.001 vs. wild-type or empty plasmid. Error bars represent the
standard deviation of the mean from 10 mice per arm. (E) DKAmice (n = 10 per arm) were infected with R. oryzae transformed with empty plasmid (2.8 x 103
spores) or R. oryzae with dual attenuated expression of FOB1 and FOB2 (2.4 x 103 spores).
doi:10.1371/journal.ppat.1004842.g008
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expressed in vivo and the reduced virulence in mice infected with R. oryzae transformed with
the RNA-i is due to attenuation of expression of both FOB genes. Finally, R. oryzae trans-
formed with the dual construct of pFOB1/FOB2 had identical virulence to R. oryzae trans-
formed with the empty plasmid in the diabetic ketoacidotic mice (Fig 8E). Collectively, these
data show that FOB1 and FOB2 are required for maximal virulence of R. oryzae only in the
deferoxamine-treated mice.
Iron uptake from ferrioxamine is dependent on the reductase/permease
pathway
Having established the importance of FOB1 and FOB2 in the uptake of iron from ferrioxamine
in vivo, we wanted to investigate the mechanism by which R. oryzae obtains iron from ferrioxa-
mine. Since one of the most common pathways of obtaining iron in fungi and R. oryzae is the
reductase/permease pathway [9], we sought to investigate if this pathway plays a role in iron
uptake from ferrioxamine. R. oryzae wild-type cells growing in medium containing ferrioxa-
mine as a sole source of iron demonstrated ~ a 3 fold increase in reductase activity when com-
pared to cells growing on medium containing iron in the form of FeCl3 (Fig 9A). Importantly,
the extracellular, membrane-impermeable ferrous chelator bathophenanthroline disulfonate
(BPS) inhibited growth of R. oryzae when ferrioxamine is used as a sole source of iron (Fig 9B).
This inhibition was due to chelating ferrous since increased concentrations of FeCl3 reversed
the inhibitory effect of BPS (Fig 9C) and the addition of BPS blocked 55Fe3+ uptake from fer-
rioxamine (Fig 9D). Similar results were obtained with the membrane-permeable ferrous
chelator bipyridyl (S5 Fig). Since ferrioxamine chelates ferric iron, this inhibition implies the
reduction of the ferric iron to ferrous prior to transportation to the fungal cell. Previously, we
have shown that targeted gene disruption of FTR1 in the multinucleated R. oryzae results in a
mutant with reduced copies of the high affinity iron permease (FTR1) rather than a completely
ftr1 null mutant [24]. This mutant with reduced copies of FTR1 had a retarded growth on me-
dium containing ferrioxamine B as a sole source of iron which implies a role for Ftr1p in iron
transport from ferrioxamine [24]. To determine if Ftr1p is required to transport the released
ferrous to the fungal cell wall, we compared the ability of this R. oryzae strain with reduced
FTR1 copy number to wild-type or PyrF-complemented strain in their ability to take up 55Fe3+
from ferrioxamine. After 6 hours of incubation with radiolabeled ferrioxamine, R. oryzae with
reduced FTR1 copy number (i.e., putative ftr1mutant) had significant decrease in taking up
55Fe3+ compared to wild-type cells (P<0.01). Moreover, after 8 hours of incubation with fer-
rioxamine, R. oryzae with reduced FTR1 copy number had significant reduction in 55Fe3+ up-
take when compared to wild-type or PyrF-complemented strains (P<0.005) (Fig 10A).
To confirm these in vitro findings, we compared the virulence of two R. oryzae with attenu-
ated expression of FTR1 to their corresponding control strains in the deferoxamine-treated
mouse model. R. oryzae strain with reduced FTR1 copy number (Fig 10B) and R. oryzae trans-
formed with RNA-i construct targeting FTR1 expression [24] (Fig 10C) had attenuated viru-
lence in the deferoxamine-treated mouse model when compared to PyrF-complemented strain
or R. oryzae transformed with the RNA-i empty plasmid, respectively. Specifically, at day 21
post infection, 30% of mice infected with reduced FTR1 copy number strain survived the infec-
tion vs. 0% for mice infected with the PyrF-complemented strain (P = 0.001) and 40% of mice
infected with R. oryzae transformed with RNA-i construct targeting FTR1 survived the infec-
tion vs. 0% survival for mice infected with R. oryzae transformed with the empty plasmid
(P = 0.013). Collectively, these results clearly show that iron transport from ferrioxamine relies,
at least in part, on the reductase/permease system.
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Potential role of other putative transporters in iron-uptake from
ferrioxamine
Because the ftr1mutants were not completely avirulent in deferoxamine-treated mice, we in-
vestigated the possibility of the involvement of other mechanisms in transporting iron from
ferrioxamine. All identified eukaryotic siderophore transporters belong to the siderophore–
iron transporters (SIT) family, a subfamily of the major facilitator superfamily [25,26,27,28].
We have conducted homology searches of the S. cerevisiae SIT genes [25,29,30], including
ARN1, ARN2, ARN3/SIT1, and ARN4 with the published R. oryzae genome data base. Al-
though the overall amino acid identity was low (i.e. 20–23%), we identified 9 ORFs that share
Fig 9. R. oryzae iron uptake from ferrioxamine is mediated by reductase activity. (A) Iron uptake from ferrioxamine is associated with increased
reductase activity as compared to iron uptake from FeCl3 (n = 4 per each time point). *P<0.03 vs. reductase activity of FeCl3 at the corresponding time point.
(B) The ferrous chelator BPS inhibits growth of R. oryzae on medium supplemented with ferrioxamine as a sole source of iron (n = 6 per group and per time
point). *P <0.006 vs. without BPS, while **P <0.006 vs. without BPS or 0.2 mM BPS. (C) FeCl3 reverses growth inhibition mediated by BPS (n = 4 per group
and per time point). (D) BPS inhibits 55Fe3+ uptake from ferrioxamine (n = 8 per group and per time point). * P<0.04 vs. without BPS and **P <0.003 vs.
without BPS or with 0.2 mM BPS. Error bars represent the standard deviation of the mean from two independent assays.
doi:10.1371/journal.ppat.1004842.g009
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homology with the S. cerevisiae SIT encoding genes and therefore potentially encode Sit pro-
teins in R. oryzae (S1 Table). We compared the pattern of expression of four of these genes
(SIT1, 4, 6, and 9) with the highest homology to S. cerevisiae SIT genes to FOB1, FOB2, and
FTR1 over time in the presence of deferoxamine or ferrioxamine as iron-poor and iron-rich
media, respectively. In iron-rich ferrioxamine medium, FOB2 expression was induced as early
as 30 min and reached a maximum expression of 9 fold increase by 24 hrs. Interestingly, FOB1
expression was significantly increased only after 24 h incubation (Fig 11A). This enhancement
of FOB gene expression was accompanied by gradual reduction in iron starvation genes (i.e.
Fig 10. Reduction of FTR1 expression decreases the ability of R. oryzae to take up iron from ferrioxamine in vitro and attenuates R. oryzae
virulence in the deferoxamine-treated mice. (A) 55Fe3+ uptake from ferrioxamine by wild-type, PyrF-complemented, or putative ftr1 strains (a strain with
reduced copies of FTR1 [24], n = 6 per arm from two independent experiments). *P<0.006 vs. wild-type or PyrF-complemented strains. **P<0.01 vs. wild-
type strain. (B) Survival of deferoxamine-treated mice (n = 10 per arm) infected with R. oryzae PyrF-complemented strain (9.4 x 102 spores), or R. oryzae
putative ftr1 null (6.5 x 102). *P = 0.001 compared to mice infected with R. oryzae PyrF-complemented strain. (C) Survival of deferoxamine-treated mice
(n = 10 per arm) infected with R. oryzae transformed with the empty plasmid (9.1 x 102 spores), or R. oryzae transformed with RNA-i construct targeting FTR1
(RNAi::ftr1) (9.5 x 102) [24]. *P = 0.013 compared to mice infected R. oryzae transformed with empty plasmid.
doi:10.1371/journal.ppat.1004842.g010
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FTR1 and SIT) that reached>99% decrease after 24 h (FTR1 and SIT9 had almost complete re-
duction in expression after 30 min of incubation) when compared to 10 min data set (Fig 11B).
In contrast and as expected, none of the FOB gene expression was enhanced in the presence of
deferoxamine (Fig 11C). Finally, FTR1 and putative SIT gene level of expression did not con-
siderably change in deferoxamine containing medium over time (level of expression fluctuated
between 0.3–1.4 fold relative to ACT1) (Fig 11D). These results confirm the induction of FOB
genes in response to ferrioxamine and that this induction changes the conditions of the fungal
cell from iron-deplete to iron-replete conditions as shown by the reduction in the iron-starva-
tion gene expression. Further, the similar pattern of SIT genes expression to the FTR1 expres-
sion in ferrioxamine containing medium suggests that these genes might play a role in iron
uptake from this siderophore.
Fig 11. FOB genes are induced in ferrioxamine containingmedium, while iron transporter genes such as FTR1 and SIT-like genes are transiently
expressed and tightly regulated. qRT-PCR was used to study the expression of FOB1, FOB2, FTR1, or SIT-like genes in media supplemented with 10 μM
ferrioxamine (A, B) or deferoxamine (C, D). Only ferrioxamine strongly induced the expression of FOB genes (A). Iron starvation genes (FTR1 and SIT-like
genes) were transiently expressed in ferrioxamine-containing medium over time (B) and expressed with minimal variation in deferoxamine-containing
medium (D). Error bars represent the standard deviation of the mean from two independent assays (n = 6 per group).
doi:10.1371/journal.ppat.1004842.g011
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Discussion
The unique predisposition of dialysis patients receiving deferoxamine for treating iron over-
load to mucormycosis has been clinically known for decades [13,15,16]. Previous data demon-
strated that Rhizopus species can utilize iron from ferrioxamine as a xenosiderophore to obtain
iron from the host [17,31,32]. This process was found to be energy dependent and possibly
doesn’t require internalization of the siderophore [18]. In this study, we have identified two
ORFs that encode Fob1 and Fob2 proteins which are required for iron uptake from ferrioxa-
mine. We introduce evidence that these proteins are receptors to which ferrioxamine binds to
during the process of obtaining iron by R. oryzae. First, Fob proteins are mainly induced by fer-
rioxamine and detected in the supernatants of regenerating R. oryzae protoplasts before they
are covalently incorporated into the nascent cell surface [33]. Second, these two proteins were
found to be expressed on the cell surface of R. oryzae, a criterion required for cell receptors.
Third, whole cell extracts from R. oryzae grown in the presence, but not the absence, of ferriox-
amine bound to radiolabeled ferrioxamine under non-denaturing conditions. Fourth, Fob2
protein isolated from whole cell extracts using anti-Fob2 antibodies also bound to radiolabeled
ferrioxamine. Finally, a mutant of R. oryzae with attenuated FOB1 and FOB2 expression bound
much less, and had retardation in, iron uptake from radiolabeled ferrioxamine versus the wild-
type strain. Collectively, these features indicate that Fob1 and Fob2 proteins are ferrioxamine
induced, surface exposed, and directly interact with the siderophore.
The identified Fob proteins were found to belong to the CBS domain family. CBS domain is
a conserved protein sequence region, which is found in all kingdoms of life [34]. It was first de-
scribed in Cystathionine β Synthase, hence the name CBS. Other proteins belonging to this
family include inosine monophosphate dehydrogenase, AMP kinase, and chloride channels.
Therefore, CBS-containing proteins functions are very diverse and could range from affecting
metabolism, multimerization and sorting of proteins, channel gating, to ligand binding. Based
on their function, CBS domain proteins can be present in the cytoplasm or associated with the
cell membrane [34]. For example, despite the lack of classical features of secreted proteins such
as N-terminal signal peptide sequence, CBS domain proteins were reported to be associated
with cell membrane in eukaryotic cells functioning as CLC chloride channels with outer mem-
brane sequence, transmembrane domain, and a cytoplasmic tail [35]. Concordant with this re-
port is our finding that Fob1p and Fob2p are predicted to be surface associated by using the
MEMSAT program (S1 Fig). In most cases, however, CBS-domain proteins bind to ligands re-
lated to adenosine, including S-adenosylmethionine (SAM), AMP, ADP [36], as well as recent-
ly reported DNA and RNA fragments [37,38]. They also have been reported to bind to metallic
ions such as Mg2+ [39]. To our knowledge, we show for the first time that a ferrioxamine recep-
tor belongs to the CBS domain family of proteins. Given the diverse function of these proteins
and the previous report of binding metallic ions, it is possible that Fob1 and Fob2 proteins on
R. oryzae cell surface bind ferrioxamine via Fe3+. This assumption is supported by our results
that only ferrioxamine, but not deferoxamine, induces the expression of FOB1 and FOB2 and
by the fact that deferoxamine was not able to competitively inhibit the uptake of radiolabeled
ferrioxamine by R. oryzae Importantly, ferric-rich siderophores are known to induce a confor-
mational change of the secondary structure of their receptors and likely explain the ability of
ferrioxamine and inability of deferoxamine to induce and bind to Fob proteins [40,41].
An apparent discrepancy in our results is the actual size of the Fob2p of ~40 kDa as indicat-
ed by the predicted sequence, the size of the rFob2p and recognized band from whole cell ex-
tracts vs. the originally isolated 70 kDa band. We initially assumed that the presence of
multiple possible N- and O-glycosylation sites might account for this increase in size of the pro-
tein due to post-translational modification. However, the isolation of Fob proteins from whole
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R. oryzae extracts at the predicted size of 40 kDa argues against a post-translational modifica-
tion of the protein. A more likely explanation is the possible oligomerization of the protein
when the sample is present in concentrated form mixed with SDS. First, the 70 kDa band was
detected in concentrated supernatants from regenerating R. oryzae protoplasts in SDS-PAGE.
Second, when we immunoprecipitated whole cell extracts from wild-type cells, the majority of
the sample remained bound to the antiFob2p antibody-coated beads and that sample contained
Fob proteins at the ~40 and ~70 kDa bands when separated on SDS-PAGE. It is prudent to
mention that cell membrane proteins are notorious for oligomerization even in denaturing
conditions when mixed with SDS [42,43]. In fact, a study found that SDS enhances the dimer-
ization of β-amyloid proteins from human cortical tissues and the level of this unnatural di-
merization increases with the increased concentration of SDS in the sample [44]. Alternatively,
CBS domain proteins were reported to oligomerize (e.g. Streptococcus pyogenes IMPDH pro-
tein [34]), therefore it is possible that Fob proteins are present as homo- or heterodimers. Our
sequence data which identified Fob2p in two independent samples detected at ~70 kDa without
the identification of Fob1p suggest that Fob2p is the major form expressed. However, it is
possible that Fob1p is expressed in low quantities and is required for the receptor activity by
forming a heterodimer with Fob1p. Investigations into the possibility of homodimer vs. hetero-
dimer formation of Fob2p and Fob1p or the possibility of induction of unnatural oligomeriza-
tion during sample processing are currently underway.
Deferoxamine is a siderophore belonging to the hydroxamate family that is mainly isolated
from bacteria including Gram-positives (e.g., Streptomyces and Nocardia) as well as Gram neg-
atives Enterobacteriaceae [45,46,47]. Up to now, deferoxamine has not been isolated from
fungi but many studies indicated the utilization of this siderophore by fungi in obtaining iron
includingMucorales, Aspergillus, Cryptococcus [17] and S. cerevisiae [25,27,48]. In addition to
utilizing deferoxamine as xenosiderophores,Mucorales are known for secreting their own side-
rophore, rhizoferrin [22,49]. However, rhizoferrin belongs to the carboxylate family which is
structurally distinct from the hydroxamate siderophores [22,50]. Interestingly, rhizoferrin
(with or without iron) did not induce the expression of FOB1 or FOB2 indicating that these
genes encode receptors specific to iron uptake from ferrioxamine. However, the ability of
Mucorales to utilize iron from structurally distinct siderophores points to the critical role iron
plays in the survival of this group of fungi.
Our in vitro data with down regulation of a single FOB gene demonstrated a modest effect
on germination, growth and iron uptake from medium supplemented with ferrioxamine.
These results can be explained by the fact that the untargeted gene was overexpressed and had
a compensatory effect. This compensatory mechanism by related genes is well documented
when other genes of the family are nullified [51]. However, this compensatory gene expression
effect did not translate into full restoration of cell surface protein to the level of R. oryzae trans-
formed with empty plasmid and grown in ferrioxamine containing medium (Fig 4D). The re-
duction of fluorescence in a single inhibition strain could be due to the possibility that the
enhancement of non-targeted gene expression did not rise to the level that would entirely com-
pensate for inhibition of the other gene. It is also possible that the gene expression of the non-
targeted gene does not localize entirely to the cell surface.
Our strategy of targeting both genes with a single construct successfully drastically attenuat-
ed the expression of FOB1 and FOB2, resulting in a significant retardation in germination,
growth and iron uptake from medium supplemented with ferrioxamine as a sole source of
iron. However, the inhibition of growth was not complete. Further, the inhibition of iron up-
take from ferrioxamine by R. oryzae with abrogated FOB1/FOB2 expression was marginally
reduced at later time points (Fig 7C, compare 4 h with earlier time points). These two phenom-
ena can be explained by the fact that old or heat-damaged ferrioxamine (due to incubation at
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37oC) is unstable and undergoes an autoreduction step to release ferrous iron [52], that is
taken up by the fungus. This assumption is corroborated by the yielding of a pink-colored com-
plex in the presence of ferrozine in our experiment. It is also probable that secondary mecha-
nisms of obtaining iron from ferrioxamine which are independent from FOB1/FOB2 are
operative. Our results with pattern of expression of SIT-like genes in medium supplemented
with ferrioxamine or deferoxamine over time supports the model of SIT-like genes being in-
volved in iron uptake from ferrioxamine. Specifically and similar to FTR1 gene, SIT-like genes
were transiently expressed as early as 10 min then the expression faded over time which indi-
cates change of the conditions of the fungal cell from iron-deplete to iron-replete conditions.
This transient expression and tight regulation is critical for the organism to avoid the toxic car-
nage of excess iron [53,54].
Importantly, a R. oryzaemutant with dual attenuation of FOB1/FOB2 expression had severe
virulence retardation in the deferoxamine-treated mice vs. mice infected with wild-type or
empty plasmid strains with 50% of the mice infected with R. oryzae transformed with RNA-i
targeting FOB1/FOB2 surviving the infection and looking healthy. It is imperative to point out
that this difference in virulence was not detected in the DKA mouse model which is consistent
with the fact that Fob1 and Fob2 are proteins induced by ferrioxamine. Fob1 and Fob2 are like-
ly dispensable in the DKA model since Fe3+ is released from transferrin by the action of acido-
sis and hyperglycemia [9,11] and transported into the fungal cell via the Ftr1p [24].
In microorganisms, the mechanism of iron uptake from ferrioxamine involves either the up-
take of the entire siderophore complex, reduction of the Fe3+ to Fe2+ to release it from the side-
rophore followed by uptake of iron via oxidase/permease system, or both. For example, in S.
cerevisiae it has been reported that both mechanisms are operative [30,55]. A previous study
demonstrated that iron uptake from ferrioxamine by R. oryzae is likely energy dependent, re-
quire a reductive step and doesn’t involve the uptake of the ferrioxamine complex [18]. In con-
trast, by using a fluorescent derivative of deferoxamine, a recent study showed that the entire
siderophore was taken up by the R. oryzae cells [56]. Our results mainly support the model by
which R. oryzae obtains iron from ferrioxamine via the reductase/permease system. First, the
reductase activity of R. oryzae when incubated with ferrioxamine far exceeds the reductase ac-
tivity when fungal cells were incubated with FeCl3. Second, the addition of the ferrous chelator
BPS inhibited growth of R. oryzae in medium with ferrioxamine as a sole source of iron and
this inhibition was due to attenuation of iron uptake from ferrioxamine. Finally, we previously
reported that a R. oryzaemutant with reduced copy number of the high affinity iron permease
(FTR1) had reduced growth on medium supplemented with ferrioxamine [24]. In this study
we show that this growth inhibition is likely due to the diminished ability of this mutant to take
iron from ferrioxamine. More significantly, we demonstrated reduced virulence in the deferox-
amine-treated mouse model of mucormycosis, even though the R. oryzaemutant with reduced
FTR1 copy number or inhibited expression of FTR1 do not have full abrogation of the function
of the permease activity [24]. However, a minor mechanism reliant on internalization of the
entire siderophore cannot be completely ruled out because the effect of BPS in vitro and the at-
tenuated virulence with ftr1mutants were not complete. It is possible that the reductase/per-
mease pathway represent a major uptake pathway for iron acquisition from ferrioxamine,
while the uptake of the siderophore by shuttle mechanism[56] represents a secondary mecha-
nism. This secondary mechanism of iron uptake from ferrioxamine is supported by the pattern
of transient and tightly regulated SIT-like gene expression in ferrioxamine containing medium
(Fig 11). Also the assumption that ferrioxamine is taken by a Sit-like shuttle transporter is a
secondary mechanism is enforced by the fact that the patchy distribution of fluorescent ferriox-
amine was observed only at the later time point of 24 hours of incubation and not earlier [56].
Consequently, we propose that R. oryzae overexpresses Fob1 and Fob2 in response to
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ferrioxamine, which accumulates in a host being treated with deferoxamine to eliminate iron
overload toxicity. These receptors bind ferrioxamine and through fungal cell surface reductase
activity, Fe3+ is released from the siderophore as Fe2+ prior to being transported across the fun-
gal cell membrane by the oxidase/permease complex (i.e., Fet3/Ftr1) to support fungal growth
and virulence (Fig 12A). In the absence of Fob1/Fob2 or the Ftr1p, this process is compromised
and the fungal virulence is reduced (Fig 12B). Also in this model, transport of the entire fer-
rioxamine siderophore by Sit-like transporter is likely to be operative as a secondary pathway.
In summary, we have identified Fob1 and Fob2 proteins as ferrioxamine receptors in R. ory-
zae. These cell surface proteins are induced by ferrioxamine and are required for mucormycosis
pathogenesis in the deferoxamine-treated mouse model. The mechanism of iron uptake from
ferrioxamine is reliant on binding of the iron-rich siderophore to its receptor, followed by
transport of iron to the fungal cell via the reductase/permease system without internalization
of the siderophore-iron complex. These two receptors appear to be conserved in at least anoth-
er fiveMucorales and can be the subject of future novel therapy to maintain the use of deferox-
amine for treating iron-overload.
Materials and Methods
Organisms and culture conditions
All organisms used in this study are listed in S2 Table. R. oryzae 99-880 is a clinical strain iso-
lated from a patient with a brain abscess and obtained from the Fungus Testing Laboratory of
University of Texas Health Science Center at San Antonio. The organism was routinely
grown on potato dextrose agar (PDA) plates (BD) for 4-5 days at 37°C. R. oryzaeM16 is a pyrF
Fig 12. Proposedmechanism of iron uptake byR. oryzae from ferrioxamine.Deferoxamine (D) directly chelates iron from transferrin (T), resulting in
ferrioxamine which binds to Fob1 and/or Fob2 proteins on the cell surface. R. oryzae then liberates Fe2+ iron by the actions of cell surface reductases then
transported into the cell by oxidase/Ftr1 complex (A). In the absence of Fob1/Fob2 or Ftr1 proteins, the ability of R. oryzae to obtain iron from ferrioxamine is
compromised and the virulence is abrogated in deferoxamine-treated mouse model (B). Sit-mediated shuttle mechanism of ferrioxamine transportation
probably acts as a secondary mechanism of iron uptake from ferrioxamine.
doi:10.1371/journal.ppat.1004842.g012
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null mutant that is derived from R. oryzae 99-880 and is unable to synthesize its own uracil
[57], was grown on YPD medium (MP Biomedicals) supplemented with 100 μg/ml uracil. R.
oryzae PyrF-complemented strain, R. oryzae with reduced FTR1 copy number, and R. oryzae
transformed with RNA-i targeting FTR1 expression were all derived from strain 99-880 and
M16 and previously described in detail [24]. In RNA-i experiments, a chemically-defined
synthetic medium containing yeast nitrogen base (YNB) supplemented with complete supple-
mental mixture without uracil (CSM-URA) (MP Biomedicals) (i.e., YNB+CSM-URA) (formu-
lation/liter, 17 g yeast nitrogen base without amino acids (YNB) (BD), 200 g dextrose, and 7.7 g
complete supplemental mixture minus uracil (CSM-URA)) was used. To count and isolate sin-
gle colonies all media above were supplemented with 0.1% Triton X-100 (Sigma). Spores were
collected in endotoxin free PBS containing 0.01% Tween 80, washed twice with PBS, and
counted with a hemacytometer for inoculum preparation.
Isolation of ferrioxamine putative receptors
To identify the R. oryzae cell surface protein(s) that interacts with ferrioxamine, freshly har-
vested R. oryzae 99-880 spores (2.5x108) were added to 50 ml YPD and pregerminated with
shaking at 37°C. After 4 hours, the spores were pelleted by centrifugation and washed twice
with 0.5 M sorbitol buffer, and suspended in 50 ml protoplasting solution which consists of 10
mM sodium phosphate, pH 6.4, 0.5 M sorbitol, 250 μg/ml lysing enzyme (Sigma), 150 μg/ml
chitinase (Sigma) and 150 μg/ml chitosanase (US Biologicals). The suspension was incubated
for ~ 2 h at 30°C with gentle shaking (100 rpm) until majority of the spores (> 90%) formed
protoplasts as determined by light microscopy examination and their sensitivity to water. Pro-
toplasts were then collected by centrifugation at low speed (100 rpm), washed twice with 0.5 M
sorbitol, and then resuspended in 10 ml YNB with amino acids containing 0.5 M sorbitol in the
presence or absence of 10 μM ferrioxamine (Sigma). The protoplasts were allowed to regener-
ate for 2 h by incubating at 37°C with gentle shaking at 100 rpm. During the early stages of this
regeneration process, many surface protein precursors are shed into the extracellular medium
but not yet covalently incorporated into the nascent cell surface, thereby enabling their easy
isolation and identification [33]. Thus, supernatants containing cell wall materials from regen-
erated protoplasts were isolated from fungal cells by centrifugation at 1000 rpm, followed by
filtration through a 0.25 μm pore-size membrane after the addition of Halt Protease Inhibitor
Cocktails (Thermo Scientific). The filtrate was then concentrated using iConcentrator tube
with molecular weight cutoff = 9.0 kDa (Thermo Scientific) and protein concentration was
measured with the Bradford method (Bio-Rad). Proteins from supernatant of regenerated pro-
toplasts in the presence or absence of ferrioxamine were separated on 10% SDS-polyacrylamide
gel (Bio-Rad) and stained with Coomassie dye R-250 (Pierce). To investigate if the proteins
from supernatant of regenerated protoplasts bind to ferrioxamine B, 25 μg of protein extract
was mixed with 55Fe-labeled ferrioxamine (for preparation, see below), and incubated for 1 h at
room temperature. The mixture was then mixed with native protein sample buffer and separat-
ed by running a native gel (Bio-Rad) in the absence of SDS and exposed to X-ray film. The can-
didate band from SDS-PAGE was cut and microsequenced using MALDITOF MS/MS (UCLA
Molecular Instrumentation Center).
Preparation of radiolabeled ferrioxamine
55Fe3+ labeled ferrioxamine was prepared as previously described [58]. Briefly, 55FeCl3 (3 μl of
3.5 Ci/mmol, Perkin Elmer) was mixed with iron-free deferoxamine B (Sigma) in a molar ratio
of 0.9:1 in a volume of 100 μl, and incubated for 2 h at room temperature. Free iron was then
removed by adding sodium phosphate (pH 7.4) followed by centrifugation at 20,000 g for 2
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min. Supernatant was diluted to 3.0 ml with ultra-pure water with a resistivity of 18.2 meg-
ohm-cm (Barnstead International, Dubuque, Iowa) and treated with 150 mg Chelex 100 resin
(Bio-Rad) twice to get rid of any residual free iron.
FOB1, FOB2, and SIT transporter expression in vitro
To quantify gene expression of putative ferrioxamine receptors and other SIT genes of R. ory-
zae in vitro, total RNA was isolated from mycelia that have been grown in YNB with amino
acids containing 10 μM of siderophore (ferrioxamine, deferoxamine, rhizoferrin with or with-
out ferric iron [EMCMicrocollections GmbH])) or varying concentrations of FeCl3 overnight
with shaking at 37°C. The RNA was isolated using RNeasy Plant Mini Kit (Qiagen) after grind-
ing the mycelia in liquid nitrogen. cDNA was synthesized from 2 μg of total RNA from each
sample after treating with Turbo DNA-free DNase I (Life Technologies) to remove any con-
taminating DNA. After removing DNase I with DNase inactivation Reagent (Life Technolo-
gies), cDNA was synthesized using RETROscript kit (Life technologies). qPCR was carried out
using the Power SYBR Green method in the StepOne Real-Time PCR System (Life Technolo-
gies) with a thermal-cycling program as follows: initial denaturing step for 10 min at 95°C, fol-
lowed by 40 cycles of denaturing at 95°C for 15 s, and annealing/elongation at 60°C for 1 min.
R. oryzae actin gene (ACT1) was used as a reference control, putative ferrioxamine receptor
gene-specific primers are listed in S3 Table. The comparative Ct method was used for analysis
[59].
Attenuation of FOB1 and FOB2 expression by RNAi
RNA-i was used to silence FOB1 or FOB2 expression individually or collectively. For individual
silencing, two reverse-complemented fragments (~450 bp) were PCR-amplified and cloned
into plasmid pRNAi-pdc-intron in an opposite direction and separated by a 100 bp-intron se-
quence, hence the total insert is ~1 kb [24]. Two constructs, termed pRNAi-FOB1 and pRNAi-
FOB2, targeting FOB1 and FOB2 expression were respectively generated. To silence both genes
at the same time, the 1 kb insert from pRNAi-FOB1 was cut and re-cloned downstream of
pRNAi-FOB2, separated by a 50-bp interval of random sequence to yield pFOB1/2. All con-
structs were transformed into R. oryzaeM16 (pyrF null mutant) using a biolistic delivery sys-
tem (Bio-Rad) as previously described [60] and transformants were selected on YNB
+CSM-URA plates supplemented with 0.1% triton. Primers used for this work are listed in S3
Table.
Growth rate determination
To compare growth rate among R. oryzae isolates on medium with ferrioxamine as a sole
source of iron, 105 spores of each strain were plated in the middle of the YNB+CSM-URA agar
plates which have been treated with 1 mM of ascorbic acid (Sigma) and 1 mM ferrozine
(Sigma) to chelate iron and then supplemented with 10 μM ferrioxamine. The plates were incu-
bated at 37°C and the diameter of the colony was calculated after 24 or 48 h.
To determine the effect of the ferrous chelators BPS or bipyridyl on the growth of R. oryzae
in the presence of ferrioxamine, R. oryzae wild-type spores (5x105/ml) were added to YNB+-
CSM-URA medium supplemented with 10 μM ferrioxamine and one of the two ferrous chela-
tors (0.2–0.8 mM of BPS or 0.2–0.4 mM bipyridyl). In some experiments, FeCl3 was added in
increased concentrations (10–1000 μM) to investigate if iron can reverse the effect of the fer-
rous chelator. Cultures were incubated at 37°C with shaking. At selected time intervals, 1 ml
sample was taken from the culture and the optical density measured at 400 nm [17].
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Germination studies
Spores from R. oryzae wild-type, transformants transformed with empty plasmid or RNA-i
constructs targeting FOB1, FOB2, or FOB1/FOB2 were harvested from their plates as above
and inoculated into YNB+CSM-URA medium supplemented with 10 μM ferrioxamine as a
sole source of iron at 5 x 106 spores/ml. The cultures were incubated at 37°C with shaking
(200 rpm). At selected time periods, a 10 μl sample was collected from each culture, and exam-
ined with a phase contrast microscope to determine if there is any effect of FOB gene silencing
on germination. Pictures were taken with a Nikon E5400 camera.
Iron uptake
To determine the ability of different strains of R. oryzae to take up iron from ferrioxamine, we
used our previously described methods [24]. Briefly, R. oryzae spores (5 x 106/ml) were pre-
germinated for 3 h in YNB medium supplemented with 1 mM ferrozine and 1 mM ascorbic
acid at 37°C with shaking. Cells were harvested by centrifugation, washed twice with assay buff-
er (YNB + 10 mM 4-morpholinepropanesulfonic acid + 1 mM ferrozine), and resuspended in
7 ml of assay buffer supplemented with 10 μM of 55Fe-labeled ferrioxamine at a concentration
of 5 x 106 spores/ml, and incubated at 37°C with shaking. In some experiments, to determine if
iron uptake from ferrioxamine required the reduction of Fe3+ to Fe2+, the ferrous chelator BPS
(0.2–0.8 mM) or bipyridyl (0.2–0.4 mM) were added to the assay buffer. At different time
points, 1 ml of sample was collected by Whatman GF/C glass filters (GE Healthcare) through a
vacuum filtration manifold (Millipore) and washed twice with cold water. Cell associated 55Fe
was counted in a liquid scintillation counter (Packard Instrument, Downers Grove, IL).
For competition studies using cold deferoxamine or ferrioxamine, 55Fe3+ uptake studies
were conducted as above while including increasing concentrations of cold deferoxamine or
ferrioxamine. Iron uptake was determined after 2 h incubation period and the results expressed
as % inhibition relative to samples run without the inclusion of cold siderophores.
Reductase activity
To determine the reductase activity of R. oryzae wild-type in the presence of ferrioxamine or
FeCl3, we used the method of Dancis et al. [61]. Briefly 5x10
7 of R. oryzae spores were cultured
in 10 ml of YNB+CSM-URA medium supplemented with 100 μM FeCl3 or 10 μM ferrioxa-
mine. The culture was incubated at 37°C with shaking. At time intervals, 1 ml of the culture
was collected, centrifuged at 3000 rpm and the spores washed twice with cold distilled water.
The spores were suspended in 1 ml of assay buffer (0.05 M sodium citrate (pH 6.5) supple-
mented with 5% glucose (w/v)). The culture was incubated at 30°C for 15 min before adding
BPS and FeCl3 to a final concentration of 1 mM for both compounds. The mixture is vortexed
and then incubated for additional 20 min, after which spores were removed by centrifugation
and the optical density of the supernatant determined at 535 nm using a blank processed simi-
larly but without any added spores. The amount of generated Fe2+ was estimated with a stan-
dard curve constructed from solutions of known Fe2+ concentrations using FeSO4.
Fob2 protein purification and antibody production
To determine the cell surface localization of the putative ferrioxamine receptors, we sought to
raise polyclonal antibodies against one of the two proteins (i.e., Fob1p or Fob2p). Since Fob1
and Fob2 predicted proteins are ~ 80% identical at the amino acid level, we chose to express
FOB2 (RO3G_11000). To express FOB2, we first PCR-amplified R. oryzae FOB2 gene (S3
Table), the PCR product was gel-purified and digested with BamHI/PstI before cloning into E.
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coli expression vector pQE32 (Qiagen) to yield pQE32/FOB2. This resulted in a construct with
6xhis tag on the N-terminus of Fob2 protein. Plasmid pQE32/FOB2 was transformed into E.
coli XL-10 gold (Agilent Technologies) and transformants isolated on Luria-Bertani (LB) agar
plates supplemented with ampicillin (100 μg/ml). Gene cloning was confirmed by DNA se-
quencing. To purify Fob2 protein, a single colony from the transformed E. coli was grown
overnight. On the second day, the culture was diluted 200 times in fresh medium containing
ampicillin, and incubated with shaking at 37°C until reaching an OD = 0.6. At this stage, 1 mM
IPTG was added to the culture which was then incubated at 37°C with shaking for additional
four hours. The bacterial cells were then harvested by centrifugation, and 6xhis tagged Fob2p
was purified to>90 homogeneity with HisPur Cobalt Purification Kit according to the instruc-
tional manual (Pierce). The purified recombinant protein was extensively dialyzed in phos-
phate buffered saline (PBS) (Mediatech, VA), and the purity and size confirmed by SDS-PAGE
analysis followed by MALDI-TOF–mass spectrometry/mass spectrometry analysis.
To generate anti-Fob2p antibodies, normal BALB/c mice were immunized by subcutaneous
injection of 20 μg recombinant Fob2p mixed in equal amounts with complete freund’s adjuvant
(CFA, Sigma-Aldrich). The mice were boosted with a subcutaneous administration of a similar
dose of the protein mixed with incomplete freund’s adjuvant (IFA) three weeks following the
initial immunization. Mice vaccinated with the diluent (i.e., PBS) mixed with CFA/IFA without
rFob2p using the same regimen served as control mice. Twelve days after the boost, blood sam-
ples were collected from mice, and anti-Fob2p Ab titers were determined by using ELISA plates
coated with Fob2p as we previously described [62]. The ELISA titer was taken as the reciprocal
of the last serum dilution that gave a positive OD reading (i.e., more than the mean OD of neg-
ative control samples plus 2 standard deviations).
Localization of Fob1 and Fob2 to the cell surface of R. oryzae
To prove Fob proteins are R. oryzaecell surface proteins, freshly harvested spores grown on
YNB+CSM-URA were pregerminted for 3–4 hours in the presence or absence of 10 μM defer-
oxamine. The pregerminated spores were incubated with the anti-Fob2p IgG at 1:100 for 1
hour on ice after a blocking step using 1.5% goat serum in PBS for 1 hour. Cells were washed 3
times with Tris-buffered saline (TBS; 0.01 M Tris HCl [pH 7.4], 0.15 M NaCl) containing
0.05% Tween 20, then counterstained with alexa 488-conjugated anti-mouse secondary at
1:100 for 1 hour on ice. The stained cells were imaged with Leica confocal microscope using an
excitation wavelength of 488 nm.
To quantify the expression of Fob proteins on R. oryzae cell surface, the pregerminated
spores were stained as above, then 1 ml samples were analyzed using a FACSCalibur (Becton
Dickinson) instrument equipped with an argon laser emitting at 488 nm. Fluorescence emis-
sion was read with a 515/40 bandpass filter. Fluorescence data were collected with logarithmic
amplifiers. The mean fluorescence intensities of 104 events were calculated using CELLQUEST
software [20,63].
Whole cell extraction, secreted proteins, western blotting and
ferrioxamine binding studies
R. oryzae (5 x 107 cells) were grown overnight in YNB+CSM-URA with or without 10 μM
ferrioxamine. Mycelia were collected by filtration, washed briefly with PBS, and then ground
thoroughly in liquid nitrogen using pestle and mortar for 3 min. The ground powder was im-
mediately transferred to microfuge tube containing 500 μl extraction buffer which consisted of
50 mM Tris-HCl, pH 7.5, 150 mMNaCl, 10 mMMgCl2. The extraction buffer was supple-
mented with 1X Halt Protease Inhibitor Cocktails (Thermo Scientific). The sample was
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vortexed vigorously for 1 min, then centrifuged for 5 min at 21000 g at 4°C. The supernatant
was transferred to a new tube and the protein concentration determined using Bradford
method.
For detecting protein secretion, supernatants from R. oryzae cells growing in YNB+CSM-
URA with or without 10 μM ferrioxamine for overnight, were collected after filtration of the
hyphal mate using 0.22 μMmembrane units (Millipore). The cell-free supernatants were con-
centrated by 200 x and the total proteins measured as above.
For Western blotting, 5 μg of each sample was used to separate proteins on an SDS-PAGE.
Separated proteins were transferred to PVDF membranes (GEWater & Process Technologies),
and treated with Western blocking reagent (Roche) for 1 h at room temperature. PVDF mem-
branes were then probed with mouse anti-Fob2p antibodies (1:100 diluted). After washing 3
times with TBS-T buffer (Tris-buffered saline + 0.05% Tween 20), the membranes were incu-
bated with HRP-conjugated sheep anti-mouse IgG (1:10,000 dilution) (Sigma-Aldrich). Fob
bands were visualized by adding the HRP substrate (SuperSignal West Dura Extended Dura-
tion Substrate, Thermo Scientific), and the chemiluminescent signal was detected using a Sony
CCD camera. In-gel tryptic digest followed by nano-liquid chromatography–tandem mass
spectrometry analysis was used to confirm the identity of the band.
Dot blots were used to determine the direct binding of radiolabeled ferrioxamine to crude
protein extracts or Fob proteins purified by immunoprecipitation using anti-Fob2p antibodies.
Briefly, anti-Fob2p antibodies (1:10 dilution) were coupled to protein G column according to
the manufacturer’s recommendation (Thermo Scientific). Protein extracts (100 μl), or bovine
serum albumin (BSA) were added to the column at room temperature for 1 h after which the
flow through is discarded followed by washing the column 3 times with PBS. 55Fe3+ labeled fer-
rioxamine was then added to the anti-Fob2 antibodies-coupled protein G column and incubat-
ed for another 1 h at room temperature. Next, the flow through is discarded and the resin was
washed three times with PBS before blotting beads containing antibody/antigen complex on
PVDF membrane followed by exposure to X-ray film.
In vivo virulence studies
The contribution of FOB to R. oryzae virulence was determined using both a deferoxamine-
treated and DKAmouse models. In both models, ICR mice (20 g) (Taconic, USA) were used.
For the deferoxamine-treated mouse model we adapted the method of Abe et al [64]. Briefly,
mice were injected i.p. with three doses of deferoxamine (100 mg/kg/per dose) given on days
-1, 0, and +1 relative to infection with R. oryzae. For the DKA mouse model, mice were ren-
dered diabetic in slight ketoacidosis with a single i.p. injection of 210 mg/kg streptozotocin in
0.2 ml citrate buffer 10 days prior to fungal challenge as we previously described [20,65,66,67].
Glycosuria and ketonuria were confirmed in all mice 7 days after streptozotocin treatment. In
both models, mice were infected with 105 spores by intravenous injection in the tail vein. Addi-
tionally, in the deferoxamine-treated model, a lower inoculum of 103 was tested. The primary
efficacy endpoint was time to moribundity. In some experiments, as a secondary endpoint, fun-
gal burden in the brains and kidneys (primary and secondary target organs) was determined 48
hours after infection by quantitative PCR assay. Briefly, mouse organs were disrupted/homoge-
nized in Lysing Matrix tubes (MP Biomedicals) using FastPrep FP120 Homogenizer (Thermo
Electron Corporation), total DNA was then isolated according to the instructional manual of
DNeasy Tissue Kit (Qiagen). qPCR was then carried out as previously described [68], using R.
oryzae-specific 18S rRNA primers (S3 Table). Values were expressed as log10 spore equivalent/
g tissue. Histopathological examination was carried out on sections of the harvested organs
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after fixing in 10% zinc formalin. The fixed organs were embedded in paraffin, and 5-mm sec-
tions were stained with H&E to detect R. oryzae hyphae [20].
For in vivo expression of FOB genes, brains and kidneys were collected from mice 48 hours
after wild-type, empty plasmid–transformed, or RNA-i transformed R. oryzae infection were
flash frozen in liquid nitrogen, disrupted/homogenized as above, and then processed for RNA
extraction using a Tri Reagent solution (Ambion). Reverse transcription was performed with
RETROscript (Ambion) using primers listed in S3 Table. For quantitative RT-PCR, SYBR
green assays were performed. Constitutively expressed ACT1 was used as a control for all reac-
tions. Calculations and statistical analyses were performed using StepOne Real-Time PCR Sys-
tem (Applied Biosystems).
Also, the contribution of the reductase/permease pathway to the pathogenesis of R. oryzae
in the deferoxamine-treated mouse model was determined by comparing the virulence of R.
oryzae with reduced copy number of FTR1 or with reduced expression of FTR1 due to RNA-i
targeting FTR1 [24], to their corresponding control strains of PyrF-complemented or R. oryzae
transformed with the empty plasmid, respectively. Infection was carried out as above with a
targeted inoculum of 1 x 103 spores. The primary efficacy endpoint was time to moribundity.
Ethics statement
All procedures involving mice were approved by the IACUC of the Los Angeles Biomedical Re-
search Institute at Harbor-UCLAMedical Center (protocol # 11671-08), according to the NIH
guidelines for animal housing and care.
Statistical analysis
Differences in FOB expression, growth rates, germination, reductase activity, iron uptake, and
tissue fungal burden were compared by the nonparametric Wilcoxon rank-sum test. The non-
parametric log-rank test was used to determine differences in survival times. A P value<0.05
was considered significant.
Supporting Information
S1 Fig. Predicted cell surface localization of Fob1 (A) and Fob2 (B) by using the MEMSAT
program. Fob proteins were predicted to have an extracellular and transmembrane domains as
well as cytoplasmic tail.
(TIF)
S2 Fig. SDS-PAGE gels of total proteins extracted from wild-type or R. oryzae dual inhibi-
tion mutant. (A) Whole cell extracts from wild-type or R. oryzae fob1/fob2 dual inhibition mu-
tant grown in the presence of absence or ferrioxamine. (B) Cell-free supernatant from cultures
of R. oryzae wild-type or fob1/fob2 dual inhibition mutants grown in the presence or absence of
ferrioxamine. (C) Immunoprecipitated samples of whole cell extracts from wild-type or R. ory-
zae fob1/fob2 dual inhibition mutant grown in the presence or absence of ferrioxamine using
anti-Fob2p antibodies. (D) Proteins from beads coated with anti-rFob2p antibodies and sub-
jected to whole cell extracts from wild-type cells grown in the presence of ferrioxamine. In all
gels, rFob2p expressed in E. coli was used as a control. Bands highlighted with boxes were se-
quenced and the sequence data is presented in Table 3.
(TIF)
S3 Fig. R. oryzae cell surface localization of Fob proteins when cells are grown in medium
containing ferrioxamine.Wild-type cells or cells transformed with empty or RNA-i plasmids
were grown in medium containing ferrioxamine as a sole source of iron prior to incubating
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with sera collected from mice immunized with recombinantly produced Fob2p. Pre immune
serum from the same mouse was used as a control. Cells were counterstained with Alexa 488
labeled anti-mouse goat antibody prior to imaging the cells with confocal microscopy. Scale
bar = 30 μM.
(TIF)
S4 Fig. RNA-i dual construct targeting FOB1 and FOB2 did not alter growth of R. oryzae
on iron-rich medium. R. oryzae 99-880 (wild-type), R. oryzae transformed with empty plas-
mid or RNA-i construct were grown at 10 fold dilution (105-102) on YNB medium without
uracil. Plates were incubated for 16 h at 37°C before measuring the diameter of the colony.
Data (n = 6) are presented as the average colony diameter (mm) + SD of the 105 inoculum.
(TIF)
S5 Fig. R. oryzae iron uptake from ferrioxamine is mediated by reductase activity. (A) The
ferrous chelator bipyridyl inhibits growth of R. oryzae on medium supplemented with ferrioxa-
mine as a sole source of iron (n = 6 per group and per time point). P<0.006 vs. without bipyr-
idyl, while P<0.006 vs. without bipyridyl or 0.2 mM bipyridyl. (B) Bipyridyl inhibits 55Fe
uptake from ferrioxamine (n = 8 per group and per each time point).  P<0.04 vs. without
bipyridyl and P<0.003 vs. without bipyridyl or with 0.2 mM bipyridyl. Error bars represent
the standard deviation of the mean from two independent assays.
(TIF)
S1 Table. Potential SIT genes of R. oryzae 99-880 identified by % amino acid identity with
S. cerevisiae SIT genes.
(DOCX)
S2 Table. Strains used in this study.
(DOCX)
S3 Table. Oligonucleotides used in this study.
(DOCX)
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